American Vanguard (AVD) 10-Q 6 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 26, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,320,010
Entity Emerging Growth Company	false
Entity Small Business	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net sales	$ 111,780	$ 89,975	$ 322,934	$ 238,553
Cost of sales	66,480	51,943	193,286	136,102
Gross profit	45,300	38,032	129,648	102,451
Operating expenses	33,635	31,570	102,011	84,175
Operating income	11,665	6,462	27,637	18,276
Interest expense, net	1,116	375	2,961	1,073
Income before provision for income taxes and loss on equity method investments	10,549	6,087	24,676	17,203
Income tax expense	3,526	1,954	6,966	5,015
Income before loss on equity method investments	7,023	4,133	17,710	12,188
Loss from equity method investments	533	115	1,051	226
Net income	6,490	4,018	16,659	11,962
Net (loss) income attributable to non-controlling interest	35	71	120	(117)
Net income attributable to American Vanguard	$ 6,525	$ 4,089	$ 16,779	$ 11,845
Earnings per common share—basic	$ 0.22	$ 0.14	$ 0.57	$ 0.41
Earnings per common share—assuming dilution	$ 0.22	$ 0.14	$ 0.56	$ 0.40
Weighted average shares outstanding—basic	29,399	29,193	29,340	29,064
Weighted average shares outstanding—assuming dilution	30,209	29,783	30,146	29,648

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 6,490	$ 4,018	$ 16,659	$ 11,962
Comprehensive income:
Foreign currency translation adjustment	638	(67)	412	970
Comprehensive income	7,128	3,951	17,071	12,932
Net (loss) income attributable to non-controlling interest	35	71	120	(117)
Comprehensive income attributable to American Vanguard	$ 7,163	$ 4,022	$ 17,191	$ 12,815

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 9,368	$ 11,337
Receivables:
Trade, net of allowance for doubtful accounts of $587 and $46, respectively	125,046	102,534
Other	12,282	7,071
Total receivables, net	137,328	109,605
Inventories, net	162,760	123,124
Prepaid expenses	11,352	10,817
Total current assets	320,808	254,883
Property, plant and equipment, net	48,315	49,321
Intangible assets, net of applicable amortization	174,801	180,950
Goodwill	21,837	22,184
Other assets	24,150	28,254
Total assets	589,911	535,592
Current liabilities:
Current installments of other liabilities	481	5,395
Accounts payable	59,769	53,748
Deferred revenue	609	14,574
Accrued program costs	61,936	39,054
Accrued expenses and other payables	11,686	12,061
Income taxes payable	3,446	1,370
Total current liabilities	137,927	126,202
Long-term debt, net of deferred loan fees	97,313	77,486
Other liabilities, excluding current installments	8,831	10,306
Deferred income tax liabilities	17,216	16,284
Total liabilities	261,287	230,278
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,757,098 shares at September 30, 2018 and 32,241,866 shares at December 31, 2017	3,276	3,225
Additional paid-in capital	81,573	75,658
Accumulated other comprehensive loss	(4,095)	(4,507)
Retained earnings	256,005	238,953
Total stockholders' equity including treasury stock	336,759	313,329
Less treasury stock at cost, 2,450,634 shares at September 30, 2018 and December 31, 2017	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	328,490	305,060
Non-controlling interest	134	254
Total stockholders’ equity	328,624	305,314
Total liabilities and stockholders' equity	$ 589,911	$ 535,592

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 587	$ 46
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	32,757,098	32,241,866
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	$ 75,658	$ (4,507)	$ 238,953	$ (8,269)	$ 305,060	$ 254
Balance (in shares) at Dec. 31, 2017	32,241,866	32,241,866				2,450,634
Adjustment to recognize new revenue recognition standard, net of tax	$ 2,214				2,214		2,214
Adjustment to recognize new standard on taxes on foreign asset transfers	(180)				(180)		(180)
Common stocks issued under ESPP	299	$ 1	298				299
Common stocks issued under ESPP, Shares		17,078
Cash dividends on common stock ($0.02 per share)	(586)				(586)		(586)
Foreign currency translation adjustment, net	672			672			672
Stock based compensation	1,309		1,309				1,309
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	511	$ 41	470				511
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes), Shares		409,979
Net income	4,605				4,655		4,655	(50)
Balance at Mar. 31, 2018	314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	75,658	(4,507)	238,953	$ (8,269)	305,060	254
Balance (in shares) at Dec. 31, 2017	32,241,866	32,241,866				2,450,634
Foreign currency translation adjustment, net	$ 412
Net income	16,659
Balance at Sep. 30, 2018	$ 328,624	$ 3,276	81,573	(4,095)	256,005	$ (8,269)	328,490	134
Balance (in shares) at Sep. 30, 2018	32,757,098	32,757,098				2,450,634
Balance at Mar. 31, 2018	$ 314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Cash dividends on common stock ($0.02 per share)	(587)				(587)		(587)
Foreign currency translation adjustment, net	(898)			(898)			(898)
Stock based compensation	1,469		1,469				1,469
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	525	$ 8	517				525
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes), Shares		74,581
Net income	5,564				5,599		5,599	(35)
Balance at Jun. 30, 2018	320,231	$ 3,275	79,721	(4,733)	250,068	$ (8,269)	320,062	169
Balance (in shares) at Jun. 30, 2018		32,743,504				2,450,634
Common stocks issued under ESPP	371	$ 1	370				371
Common stocks issued under ESPP, Shares		18,872
Cash dividends on common stock ($0.02 per share)	(588)				(588)		(588)
Foreign currency translation adjustment, net	638			638			638
Stock based compensation	1,457		1,457				1,457
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	25		25				25
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes), Shares		(5,278)
Net income	6,490				6,525		6,525	(35)
Balance at Sep. 30, 2018	$ 328,624	$ 3,276	$ 81,573	$ (4,095)	$ 256,005	$ (8,269)	$ 328,490	$ 134
Balance (in shares) at Sep. 30, 2018	32,757,098	32,757,098				2,450,634

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.015	$ 0.02	$ 0.02

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net income	$ 16,659	$ 11,962
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	14,233	12,358
Amortization of other long term assets	3,630	3,995
Amortization of discounted liabilities	314	20
Stock-based compensation	4,235	3,585
(Decrease) increase in deferred income taxes	(34)	6
Loss from equity method investments	1,051	226
Changes in assets and liabilities associated with operations:
Increase in net receivables	(24,382)	(15,746)
Increase in inventories	(39,305)	(2,213)
Increase in prepaid expenses and other assets	(959)	(3,678)
Increase (decrease) in income tax receivable/payable, net	2,069	(12,137)
Increase in accounts payable	5,711	4,556
Decrease in deferred revenue	(13,965)	(3,848)
Increase in accrued program costs	22,882	22,720
Decrease in other payables and accrued expenses	(7,229)	(3,562)
Net cash (used) provided by operating activities	(15,090)	18,244
Cash flows from investing activities:
Capital expenditures	(5,154)	(5,333)
Investments		(950)
Acquisition of product lines and other intangible assets	(1,634)	(25,904)
Net cash used in investing activities	(6,788)	(32,187)
Cash flows from financing activities:
Payments under line of credit agreement	(71,125)	(59,025)
Borrowings under line of credit agreement	90,800	76,000
Payments on other long-term liabilities		(26)
Net payments from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholding)	1,731	(820)
Payment of cash dividends	(1,611)	(1,161)
Net cash provided by financing activities	19,795	14,968
Net (decrease) increase in cash and cash equivalents	(2,083)	1,025
Effect of exchange rate changes on cash and cash equivalents	114	151
Cash and cash equivalents at beginning of period	11,337	7,869
Cash and cash equivalents at end of period	$ 9,368	$ 9,045

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue Recognition	2. Revenue Recognition—The Company recognizes revenue from the sale of its products, which include insecticides, herbicides, soil fumigants, and fungicides. The Company sells its products to customers, which include distributors and retailers. In addition, the Company recognizes royalty income from the sale of intellectual property. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended Sept 30, 2018 Nine Months Ended Sept 30, 2018 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 25,475 $ 25,481 $ 99,433 $ 99,463 Herbicides/soil fumigants/fungicides 34,577 34,577 98,163 98,163 Other, including plant growth regulators and distribution 35,302 35,302 83,519 83,519 95,354 95,360 281,115 281,145 Non-crop, including distribution 16,426 16,426 41,819 41,819 Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964 Net sales: US $ 71,711 $ 71,717 $ 205,889 $ 205,919 International 40,069 40,069 117,045 117,045 Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964 Timing of revenue recognition: Goods transferred at a point in time $ 111,675 $ 111,786 $ 322,266 $ 322,964 Goods and services transferred over time 105 — 668 — Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964 In May 2014, Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers Effective January 1, 2018, the Company adopted ASC 606 using the modified retrospective method, therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less (ii) allowing entities the option to treat shipping and handling activities that occur after control of the good transfers to the customer as fulfillment activities. For all of the Company’s sales and distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs at shipment for product sales, but also occurs over time for certain products that are deemed to have no alternative use accompanied by an enforceable right to payment for performance completed to date. For revenue recognized over time, the Company uses an output measure, units produced, to measure progress. From time to time, the Company may offer a program to eligible customers, in good standing, that provides extended payment terms on a portion of the sales on selected products. The Company analyzes these extended payment programs in connection with its revenue recognition policy to ensure all revenue recognition criteria are satisfied at the time of sale. Performance Obligations — A performance obligation is a promise in a contract or sales order to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. A transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of the Company’s sales orders have multiple performance obligations, as the promise to transfer individual goods or services is separately identifiable from other promises in the sales orders. For sales orders with multiple performance obligations, the Company allocates the sales order’s transaction price to each performance obligation based on its relative stand-alone selling price. The stand-alone selling prices are determined based on the prices at which the Company separately sells these products. The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. At September 30, 2018, the Company had $24,599 of remaining performance obligations, which are comprised of open sales orders, deferred revenue and services not yet delivered. The Company expects to recognize approximately all of its remaining performance obligations as revenue in fiscal 2018. Contract Balances — The timing of revenue recognition, billings and cash collections may result in deferred revenue in the condensed consolidated balance sheets. The Company sometimes receives payments from its customers in advance of goods and services being provided in return for early cash incentive programs, resulting in deferred revenues. These liabilities are reported on the condensed consolidated balance sheet at the end of each reporting period. September 30, 2018 December 31, 2017 Total receivables, net $ 137,328 $ 109,605 Contract assets 3,000 — Deferred revenue 609 14,574 Revenue recognized for the three and nine months ended September 30, 2018, that was included in the deferred revenue balance at the beginning of 2018 was $13,965. The following table presents the effect of the adoption of ASC 606 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017, (in thousands): As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated statements of operations for the three and nine months ended September 30, 2018 were $2 and $59, respectively, reductions in net sales. This revenue will move from being recognized at point in time to be recognized over time. As such, the net sales will be reported as sales in later quarters. In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheets was as follows: As of September 30, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 609 550 59 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 256,005 253,791 2,214

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	3. Property, plant and equipment at September 30, 2018 and December 31, 2017 consists of the following: September 30, 2018 December 31, 2017 Land $ 2,548 $ 2,458 Buildings and improvements 16,832 16,678 Machinery and equipment 108,033 107,722 Office furniture, fixtures and equipment 5,001 4,925 Automotive equipment 1,102 735 Construction in progress 2,483 1,917 Total gross value 135,999 134,435 Less accumulated depreciation (87,684 ) (85,114 ) Total net value $ 48,315 $ 49,321 The Company recognized depreciation expense related to property, plant and equipment of $2,020 and $2,033 for the three months ended September 30, 2018 and 2017, respectively. During the three months ended September 30, 2018 and 2017, the Company eliminated from assets and accumulated depreciation $249 and $1,126, respectively, of fully depreciated assets. The Company recognized depreciation expense related to property, plant and equipment of $6,166 and $6,112 for the nine months ended September 30, 2018 and 2017, respectively. During the nine months ended September 30, 2018 and 2017, the Company eliminated from assets and accumulated depreciation $3,596 and $5,884, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	4. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: September 30, 2018 December 31, 2017 Finished products $ 144,963 $ 107,595 Raw materials 17,797 15,529 $ 162,760 $ 123,124 At September 30, 2018 and December 31, 2017, inventory reserve amounted to $1,673 and $3,137, respectively. Included in this change, during the three and nine months ended September 30, 2018, we adjusted our expected future costs for the re-work and released $696 to income as a consequence. As of September 30, 2018, we believe our inventories are valued at lower of cost or net realizable value. In July 2015, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASU”) 2015-11, Inventory (Topic 330). Topic 330 required an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this new standard effective January 1, 2017. There was no impact on this adoption.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	5. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net sales: Insecticides $ 25,475 $ 24,866 $ 99,433 $ 102,249 Herbicides/soil fumigants/fungicides 34,577 32,717 98,163 68,783 Other, including plant growth regulators 35,302 17,191 83,519 30,680 Total crop: 95,354 74,774 281,115 201,712 Non-crop 16,426 15,201 41,819 36,841 Total net sales: $ 111,780 $ 89,975 $ 322,934 $ 238,553 Net sales: US $ 71,711 $ 65,842 $ 205,889 $ 173,877 International 40,069 24,133 117,045 64,676 Total net sales: $ 111,780 $ 89,975 $ 322,934 $ 238,553

Accrued Program Costs

Accrued Program Costs	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Accrued Program Costs	6. Accrued Program Costs The Company offers various discounts to customers based on the volume purchased within a defined time period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments made to distributors, retailers or growers, at the end of a growing season. The Company describes these payments as “Programs.” Programs are a critical part of doing business in both the US crop and non-crop chemicals market places. These discount Programs represent variable consideration. In accordance with ASC 606, revenue from sales is recorded at the net sales price, which is the transaction price, and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to its customers estimated using the expected value method. Each quarter management compares individual sale transactions with Programs to determine what, if any, estimated program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated Program balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in agreed upon terms and conditions attached to each Program. Following this assessment, management will make adjustments to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at, or close to, the end of the crop season, at which time customer performance can be more fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year. No significant changes in estimates were made during the three and nine months ended September 30, 2018 and 2017, respectively.

Cash Dividend

Cash Dividend	9 Months Ended
	Sep. 30, 2018
Cash Dividends [Abstract]
Cash Dividend	7. The Company has declared and/or paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid September 18, 2018 October 3, 2018 October 17, 2018 $ 0.020 $ 588 June 11, 2018 June 28, 2018 July 12, 2018 $ 0.020 $ 587 March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	8. ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator: Net income attributable to AVD $ 6,525 $ 4,089 $ 16,779 $ 11,845 Denominator: (in thousands) Weighted average shares outstanding-basic 29,399 29,193 29,340 29,064 Dilutive effect of stock options and grants 810 590 806 584 30,209 29,783 30,146 29,648 For the three and nine months ended September 30, 2018 and 2017, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Indebtedness	9. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at September 30, 2018 and December 31, 2017. The Company has no short term debt as of September 30, 2018 and December 31, 2017. The revolving line of credit is summarized in the following table: Long-term indebtedness ($000's) September 30, 2018 December 31, 2017 Revolving line of credit $ 98,100 $ 78,425 Deferred loan fees (787 ) (939 ) Net long-term debt $ 97,313 $ 77,486 As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. At September 30, 2018, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $105,111. This compares to an available borrowing capacity of $124,724 as of September 30, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

Reclassification

Reclassification	9 Months Ended
	Sep. 30, 2018
Text Block [Abstract]
Reclassification	10. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the September 30, 2018 presentation.

Comprehensive income

Comprehensive income	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Comprehensive income	11. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three and nine month periods ended September 30, 2018 and 2017, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	12. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and nine months ended September 30, 2018 and 2017. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Nine months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) September 30, 2018 Restricted Stock $ 966 $ 2,716 $ 6,206 2.0 Performance Based Restricted Stock 491 1,519 2,814 2.0 Total $ 1,457 $ 4,235 $ 9,020 September 30, 2017 Incentive Stock Options $ 80 $ 250 $ 94 0.3 Restricted Stock 635 2,068 4,475 1.2 Performance Based Restricted Stock 299 920 1,901 2.0 Performance Based Options 249 347 69 0.3 Total $ 1,263 $ 3,585 $ 6,539 Stock Options—During the three and nine months ended September 30, 2018, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 473,641 $ 9.38 $ 9.38 Options exercised (40,923 ) 11.49 — Balance outstanding, March 31, 2018 432,718 9.19 9.19 Options exercised (38,360 ) 10.02 — Balance outstanding, June 30, 2018 394,358 9.12 9.12 Options exercised (9,568 ) 9.82 — Balance outstanding, September 30, 2018 384,790 $ 9.11 $ 9.11 Information relating to stock options at September 30, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 229,545 26 $ 7.5 229,545 $ 7.50 $11.32—$14.75 155,245 73 11.48 155,245 11.48 384,790 $ 9.11 384,790 $ 9.11 The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of September 30, 2018, were as follows: As of September 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 384,790 $ 9.11 45 $ 3,422 Expected to Vest 384,790 $ 9.11 45 $ 3,422 Exercisable 384,790 $ 9.11 45 $ 3,422 Common stock grants — Nine Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.61 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 17.41 559,587 15.38 Granted 22,308 23.66 38,502 17.08 Vested (20,313 ) 22.82 (188,400 ) 15.22 Forfeited (6,424 ) 17.25 (6,593 ) 15.55 Nonvested shares at June 30th 628,231 17.40 403,096 15.61 Granted — — 1,000 19.90 Vested (17,591 ) 13.51 (1,065 ) 12.88 Forfeited (13,659 ) 17.35 (5,209 ) 15.80 Nonvested shares at September 30th 596,981 $ 17.51 397,822 $ 15.63 Common stock grants — During the nine months ended September 30, 2018, the Company issued a total of 277,280 shares of common stock to employees and directors of which 19,313 shares vested immediately, 19,760 shares will vest between a range of 178 days to 1,060 days, and the remaining shares will cliff vest after three years of service. The shares granted in 2018 were average fair valued at $20.27 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the value of restricted shares over the required service period. During the nine months ended September 30, 2017, the Company issued a total of 290,977 shares of common stock to employees and directors. 24,312 shares vested immediately, 3,900 shares will vest in three equal tranches on the employee’s anniversaries, 1,000 shares will cliff vest after one year of service, 2,500 shares will cliff vest after two years of service, and the remaining shares will cliff vest after three years of service. The shares granted in 2017 were average fair valued at $16.24 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the value of restricted shares over the required service period. During the three months ended September 30, 2018 and 2017, the Company recognized stock-based compensation related to restricted shares of $966 and $635, respectively. During the nine months ended September 30, 2018 and 2017, the Company recognized stock-based compensation related to restricted shares of $2,716 and $2,068 respectively. As of September 30, 2018, the Company had approximately $6,206 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.0 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Nine Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.79 121,194 15.40 Vested (14,625 ) 11.01 — — Forfeited (1,765 ) 15 — — Nonvested shares at March 31 st 292,113 16.74 240,216 14.80 Granted 3,850 22.69 7,400 15.88 Vested — — (48,046 ) 14.92 Forfeited (2,179 ) 17.67 (12,560 ) 12.92 Nonvested shares at June 30th 293,784 16.81 187,010 14.93 Additional vesting based on performance 4,036 13.53 — — Vested (8,232 ) 13.47 — — Forfeited (1,870 ) 15.67 (953 ) 15.21 Nonvested shares at September 30th 287,718 $ 16.87 186,057 $ 14.93 Performance Based Shares — During the nine months ended September 30, 2018, the Company issued a total of 130,332 performance based shares to employees. The shares granted during the first nine months of 2018 have an average fair value of $18.74. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. During the nine months ended September 30, 2017, the Company issued a total of 128,594 performance based shares to employees. The shares granted during the first nine months of 2017 have an average fair value of $15.43. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. As of September 30, 2018, performance based shares related to EBIT and net sales have an average fair value of $18.27 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $15.43 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended September 30, 2018 and 2017, the Company recognized stock-based compensation related to performance based shares of $491 and $299, respectively. During the nine months ended September 30, 2018 and 2017, the Company recognized stock-based compensation related to performance based shares of $1,519 and $920, respectively. As of September 30, 2018, the Company had approximately $2,814 of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.0 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the nine months ended September 30, 2018 and 2017, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49 $ 11.49 Additional vesting based on performance 77,598 11.49 — Options exercised (11,839 ) 11.49 11.49 Balance outstanding, June 30, 2018 141,425 11.49 $ 11.49 Options forfeited (1,014 ) 11.49 11.49 Balance outstanding, September 30, 2018 140,411 $ 11.49 $ 11.49 Information relating to stock options at September 30, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 140,411 75 $ 11.49 140,411 $ 11.49 The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2018 are as follows: As of September 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 140,411 $ 11.49 75 $ 914 Expected to Vest 140,411 $ 11.49 75 $ 914 Exercisable 140,411 $ 11.49 75 $ 914 In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718)

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	13. Legal Proceedings— In accordance with U.S. GAAP, the Company records a liability in its condensed consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. These liabilities include those relating to threatened or pending litigation and government proceedings. To the extent that any such litigation or proceeding is material to the Company or its property, such matter (including any loss contingency associated therewith) is reported as per Item 103 of Regulation S-K in Item 1 of Part II of this Form 10Q.

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	14. Recently Issued Accounting Guidance — In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement-Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income: The standard permits a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Cuts and Jobs Act (the “Act”). The GILTI provisions imposed a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has considered options regarding the accounting treatment for any potential GILTI inclusions and has elected to treat such inclusions as period costs. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350). In October 2016, FASB issued ASU 2016-16, Income Taxes (ASC 740) In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (ASC 230) In February 2016, FASB issued ASU 2016-02, Leases In February 2016, FASB issued ASU 2016-02, Leases, as amended by ASU 2018-11 issued in July 2018, which provides entities with an additional optional transition method to adopt the new lease standard, as well as a practical expedient for lessors on non-lease components. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company plans to adopt ASU 2016-02 and the transition amendments provided by ASU 2018-11, on the effective date of January 1, 2019. The Company plans to elect transition-related accounting policies under ASU 2016-02, which allow entities to not reassess, as of the adoption date, (1) any expired or existing contracts that are leases or contain leases, (2) the classification of any expired or existing leases and (3) initial direct costs for any existing leases. The Company plans to apply ASU 2016-02 to all leases over 12 months in length. The Company is completing its analysis of this ASU and the impact it will have on its consolidated financial statements, but we expect this adoption will result in a material increase in the assets and liabilities on our consolidated balance sheet. The Company has not determined if the adoption of this standard will materially impact our operating results. The evaluation includes an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." The amendment requires (i) equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, (ii) public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes and (iii) separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables). This amendment eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. This amendment is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes during the three and nine months ended September 30, 2018. If there are any observable price changes related to this investment or a similar investment of the same issuer in fiscal years beginning after December 15, 2017, the Company would be required to assess the fair value impact, if any, on each class of stock, and write the individual security interest up or down to its estimated fair value, which could have a significant effect on the Company's financial position and results of operations. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	15. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank. During the nine months ended September 30, 2018, net measurement period adjustments in the amounts of $1,146 was made to reduce provisional amounts recorded for deferred consideration in connection with the 2017 AgriCenter acquisition resulting in a reduction to goodwill. There was no similar adjustment to goodwill made during the three months ended September 30, 2018. As of September 30, 2018, the Company reassessed the fair value of the deferred consideration balances relating to the 2017 AgriCenter and OHP acquisitions, which resulted in a combined reduction of the deferred consideration balances of approximately $3,969 and $5,437, which has been reflected as a reduction to general and administrative expenses within operating expenses in the condensed consolidated statements of operations for the three months and nine months ended September 30, 2018, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss ("AOCI")	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Accumulated Other Comprehensive Loss ("AOCI")	16. Accumulated Other Comprehensive Loss (“AOCI”) — Total Balance, December 31, 2017 $ (4,507 ) FX translation 672 Balance, March 31, 2018 (3,835 ) FX translation (898 ) Balance, June 30, 2018 (4,733 ) FX translation 638 Balance, September 30, 2018 $ (4,095 )

Investments

Investments	9 Months Ended
	Sep. 30, 2018
Equity Method Investments And Joint Ventures [Abstract]
Investments	17. Investments — TyraTech Inc. (“TyraTech”) is a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. In January 2018, TyraTech finalized a stock repurchase as a result of which the Company’s ownership position in TyraTech increased from approximately 15.11% to approximately 34.38%. The Company utilizes the equity method of accounting with respect to this investment. Accordingly, our net income includes income and losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses and impairment charges (if appropriate). For the three and nine months ended September 30, 2018, the Company recognized a net loss of $352 and $795 as a result of the Company’s ownership position in TyraTech. The Company recognized a loss of $29 and $140 for the three and nine months ended September 30, 2017. On June 27, 2017, both Amvac Netherlands BV and Huifeng Agrochemical Company, Ltd (“Huifeng”) made individual capital contributions of $950 to Huifeng Amvac Innovation Co. Ltd (“Hong Kong Joint Venture”). As of September 30, 2018, the Company’s ownership position in the Hong Kong Joint Venture was 50%. The Company utilizes the equity method of accounting with respect to this investment. On July 7, 2017, the Hong Kong Joint Venture purchased the shares of Profeng Australia, Pty Ltd.(“Profeng”), for a total consideration of $1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via its wholly owned subsidiary Shanghai Biological Focus center. For the three and nine months ended September 30, 2018, the Company recognized losses of $182 and $256, respectively, as a result of the Company’s ownership position in the Hong Kong Joint Venture. The Company recognized a net loss of $86 and $86 for the three and nine months ended September 30, 2017. In February 2016, AMVAC Netherlands BV made an investment in Biological Products for Agriculture (“Bi-PA”). Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of September 30, 2018, the Company’s ownership position in Bi-PA was 15%. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes in the three and nine months ended September 30, 2018. There was no impairment on the investment as of September 30, 2018. The investment is not material and is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes – Income tax expense increased by $1,572 to end at an expense of $3,526 for the three months ended September 30, 2018, as compared to $1,954 for the comparable period in 2017. The tax charge for the quarter included a one-time adjustment in the amount of $1,089 related to the transition tax element of the Tax Cuts and Jobs Act that was signed into law in December 2017. During the third quarter of 2018 we concluded our review of all historical international tax returns and determined that our liability was higher than estimated initially and accordingly we recorded an adjustment to tax expense in our September 30, 2018 condensed consolidated financial statements pursuant to the guidance in SAB 118. The effective tax rate for the quarter was 33.4%, as compared to 32.1% in the same period of the prior year. This included the adjustment of $1,089 and, if excluded, the effective tax rate would have been 23.1%. Income tax expense was $6,966 for the nine months ended September 30, 2018, as compared to $5,015 for the nine months ended September 30, 2017. The effective tax rate for the nine months ended September 30, 2018 and 2017 was 28.2% and 29.2%, respectively. As with the quarter, the nine month period is impacted by the transition tax adjustment of $1,089. Excluding that one-time charge, our tax rate would have been 23.8%. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management. In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; and (ii) requiring companies to pay a one-time transition tax on certain unremitted earnings of foreign subsidiaries. The Act also established new tax laws that affect 2018, including, but not limited to: (i) the reduction of the U.S. federal corporate tax rate discussed above; (ii) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (iii) a new provision designed to tax global intangible low-taxed income (“GILTI”); (iv) the repeal of the domestic production activity deductions; (v) limitations on the deductibility of certain executive compensation; and (vi) limitations on the use of foreign tax credits to reduce the U.S. income tax liability. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. Additional work including a more detailed analysis of the Company's deferred tax assets and liabilities and its historical foreign earnings as well as potential correlative adjustments were completed as of the quarter ended September 30, 2018. In this regard, as noted above, the company recorded an expense in the current quarter of $1,089 for the transition tax.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events – On October 31, 2018 during a special meeting, shareholders of Tyratech, Inc. approved both i) an agreement and plan of merger by which the Company will acquire the remaining 65.62% of the issued and outstanding shares of Tyratech stock for cash in the amount of approximately $4,340 and ii) cancellation of Tyratech’s listing on the AIM market of the London Stock Exchange. The Company expects the transaction, including the delisting of shares, to close on November 8, 2018. On November 5, 2018, the Company’s announced that on November 2, 2018, its Board of Directors authorized management to commence the re-purchase of up to $20,000 worth of its common stock on the open market, depending upon market conditions over the short to mid-term. On November 5, 2018, Envance Technologies, LLC, a majority-owned subsidiary of the Company, announced that it had entered into an exclusive, global joint development and license agreement with The Procter & Gamble Company (“P&G”). Under the agreement, Envance will work with P&G Ventures to develop a range of new insect control solutions that leverage Envance’s bio-science formulas designed to quickly kill and control insects by targeting nervous system receptors only active in bugs. Further details of the arrangement were not disclosed.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Summary of Contract Balances	September 30, 2018 December 31, 2017 Total receivables, net $ 137,328 $ 109,605 Contract assets 3,000 — Deferred revenue 609 14,574
Accounting Standards Update 2014-09
Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region	Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended Sept 30, 2018 Nine Months Ended Sept 30, 2018 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 25,475 $ 25,481 $ 99,433 $ 99,463 Herbicides/soil fumigants/fungicides 34,577 34,577 98,163 98,163 Other, including plant growth regulators and distribution 35,302 35,302 83,519 83,519 95,354 95,360 281,115 281,145 Non-crop, including distribution 16,426 16,426 41,819 41,819 Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964 Net sales: US $ 71,711 $ 71,717 $ 205,889 $ 205,919 International 40,069 40,069 117,045 117,045 Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964 Timing of revenue recognition: Goods transferred at a point in time $ 111,675 $ 111,786 $ 322,266 $ 322,964 Goods and services transferred over time 105 — 668 — Total net sales: $ 111,780 $ 111,786 $ 322,934 $ 322,964
Summary of Impact of Adoption of ASC 606 to Condensed Consolidated Balance Sheets	The following table presents the effect of the adoption of ASC 606 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017, (in thousands): As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheets was as follows: As of September 30, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 609 550 59 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 256,005 253,791 2,214

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at September 30, 2018 and December 31, 2017 consists of the following: September 30, 2018 December 31, 2017 Land $ 2,548 $ 2,458 Buildings and improvements 16,832 16,678 Machinery and equipment 108,033 107,722 Office furniture, fixtures and equipment 5,001 4,925 Automotive equipment 1,102 735 Construction in progress 2,483 1,917 Total gross value 135,999 134,435 Less accumulated depreciation (87,684 ) (85,114 ) Total net value $ 48,315 $ 49,321

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: September 30, 2018 December 31, 2017 Finished products $ 144,963 $ 107,595 Raw materials 17,797 15,529 $ 162,760 $ 123,124

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net sales: Insecticides $ 25,475 $ 24,866 $ 99,433 $ 102,249 Herbicides/soil fumigants/fungicides 34,577 32,717 98,163 68,783 Other, including plant growth regulators 35,302 17,191 83,519 30,680 Total crop: 95,354 74,774 281,115 201,712 Non-crop 16,426 15,201 41,819 36,841 Total net sales: $ 111,780 $ 89,975 $ 322,934 $ 238,553 Net sales: US $ 71,711 $ 65,842 $ 205,889 $ 173,877 International 40,069 24,133 117,045 64,676 Total net sales: $ 111,780 $ 89,975 $ 322,934 $ 238,553

Cash Dividend (Tables)

Cash Dividend (Tables)	9 Months Ended
	Sep. 30, 2018
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and/or paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid September 18, 2018 October 3, 2018 October 17, 2018 $ 0.020 $ 588 June 11, 2018 June 28, 2018 July 12, 2018 $ 0.020 $ 587 March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Numerator: Net income attributable to AVD $ 6,525 $ 4,089 $ 16,779 $ 11,845 Denominator: (in thousands) Weighted average shares outstanding-basic 29,399 29,193 29,340 29,064 Dilutive effect of stock options and grants 810 590 806 584 30,209 29,783 30,146 29,648

Indebtedness (Tables)

Indebtedness (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Summary of Revolving Line of Credit	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at September 30, 2018 and December 31, 2017. The Company has no short term debt as of September 30, 2018 and December 31, 2017. The revolving line of credit is summarized in the following table: Long-term indebtedness ($000's) September 30, 2018 December 31, 2017 Revolving line of credit $ 98,100 $ 78,425 Deferred loan fees (787 ) (939 ) Net long-term debt $ 97,313 $ 77,486

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and nine months ended September 30, 2018 and 2017. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Nine months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) September 30, 2018 Restricted Stock $ 966 $ 2,716 $ 6,206 2.0 Performance Based Restricted Stock 491 1,519 2,814 2.0 Total $ 1,457 $ 4,235 $ 9,020 September 30, 2017 Incentive Stock Options $ 80 $ 250 $ 94 0.3 Restricted Stock 635 2,068 4,475 1.2 Performance Based Restricted Stock 299 920 1,901 2.0 Performance Based Options 249 347 69 0.3 Total $ 1,263 $ 3,585 $ 6,539
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 473,641 $ 9.38 $ 9.38 Options exercised (40,923 ) 11.49 — Balance outstanding, March 31, 2018 432,718 9.19 9.19 Options exercised (38,360 ) 10.02 — Balance outstanding, June 30, 2018 394,358 9.12 9.12 Options exercised (9,568 ) 9.82 — Balance outstanding, September 30, 2018 384,790 $ 9.11 $ 9.11
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at September 30, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 229,545 26 $ 7.5 229,545 $ 7.50 $11.32—$14.75 155,245 73 11.48 155,245 11.48 384,790 $ 9.11 384,790 $ 9.11
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of September 30, 2018, were as follows: As of September 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 384,790 $ 9.11 45 $ 3,422 Expected to Vest 384,790 $ 9.11 45 $ 3,422 Exercisable 384,790 $ 9.11 45 $ 3,422
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49 $ 11.49 Additional vesting based on performance 77,598 11.49 — Options exercised (11,839 ) 11.49 11.49 Balance outstanding, June 30, 2018 141,425 11.49 $ 11.49 Options forfeited (1,014 ) 11.49 11.49 Balance outstanding, September 30, 2018 140,411 $ 11.49 $ 11.49
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at September 30, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 140,411 75 $ 11.49 140,411 $ 11.49
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2018 are as follows: As of September 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 140,411 $ 11.49 75 $ 914 Expected to Vest 140,411 $ 11.49 75 $ 914 Exercisable 140,411 $ 11.49 75 $ 914
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Nine Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.61 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 17.41 559,587 15.38 Granted 22,308 23.66 38,502 17.08 Vested (20,313 ) 22.82 (188,400 ) 15.22 Forfeited (6,424 ) 17.25 (6,593 ) 15.55 Nonvested shares at June 30th 628,231 17.40 403,096 15.61 Granted — — 1,000 19.90 Vested (17,591 ) 13.51 (1,065 ) 12.88 Forfeited (13,659 ) 17.35 (5,209 ) 15.80 Nonvested shares at September 30th 596,981 $ 17.51 397,822 $ 15.63
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Shares — Nine Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.79 121,194 15.40 Vested (14,625 ) 11.01 — — Forfeited (1,765 ) 15 — — Nonvested shares at March 31 st 292,113 16.74 240,216 14.80 Granted 3,850 22.69 7,400 15.88 Vested — — (48,046 ) 14.92 Forfeited (2,179 ) 17.67 (12,560 ) 12.92 Nonvested shares at June 30th 293,784 16.81 187,010 14.93 Additional vesting based on performance 4,036 13.53 — — Vested (8,232 ) 13.47 — — Forfeited (1,870 ) 15.67 (953 ) 15.21 Nonvested shares at September 30th 287,718 $ 16.87 186,057 $ 14.93

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss ("AOCI") (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2017 $ (4,507 ) FX translation 672 Balance, March 31, 2018 (3,835 ) FX translation (898 ) Balance, June 30, 2018 (4,733 ) FX translation 638 Balance, September 30, 2018 $ (4,095 )

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)Segment	Sep. 30, 2017USD ($)
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Number of reportable segments | Segment			1
Remaining performance obligations	$ 24,599		$ 24,599
Revenue recognized	13,965		13,965
Net sales	111,780	$ 89,975	322,934	$ 238,553
Accounting Standards Update 2014-09 | Impact of Adoption of ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net sales	$ (2)		$ (59)

Summary of Selective Enterprise

Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation Of Revenue [Line Items]
Net sales	$ 111,780	$ 89,975	$ 322,934	$ 238,553
Insecticides
Disaggregation Of Revenue [Line Items]
Net sales	25,475	24,866	99,433	102,249
Herbicides/Soil Fumigants/Fungicides
Disaggregation Of Revenue [Line Items]
Net sales	34,577	32,717	98,163	68,783
Other, Including Plant Growth Regulators and Distribution
Disaggregation Of Revenue [Line Items]
Net sales	35,302		83,519
Crop
Disaggregation Of Revenue [Line Items]
Net sales	95,354	74,774	281,115	201,712
Non-crop, Including Distribution
Disaggregation Of Revenue [Line Items]
Net sales	16,426		41,819
US
Disaggregation Of Revenue [Line Items]
Net sales	71,711	65,842	205,889	173,877
International
Disaggregation Of Revenue [Line Items]
Net sales	40,069	$ 24,133	117,045	$ 64,676
Goods Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Net sales	111,675		322,266
Goods and Services Transferred Over Time
Disaggregation Of Revenue [Line Items]
Net sales	105		668
Balances without adoption of ASC 606
Disaggregation Of Revenue [Line Items]
Net sales	111,786		322,964
Balances without adoption of ASC 606 | Insecticides
Disaggregation Of Revenue [Line Items]
Net sales	25,481		99,463
Balances without adoption of ASC 606 | Herbicides/Soil Fumigants/Fungicides
Disaggregation Of Revenue [Line Items]
Net sales	34,577		98,163
Balances without adoption of ASC 606 | Other, Including Plant Growth Regulators and Distribution
Disaggregation Of Revenue [Line Items]
Net sales	35,302		83,519
Balances without adoption of ASC 606 | Crop
Disaggregation Of Revenue [Line Items]
Net sales	95,360		281,145
Balances without adoption of ASC 606 | Non-crop, Including Distribution
Disaggregation Of Revenue [Line Items]
Net sales	16,426		41,819
Balances without adoption of ASC 606 | US
Disaggregation Of Revenue [Line Items]
Net sales	71,717		205,919
Balances without adoption of ASC 606 | International
Disaggregation Of Revenue [Line Items]
Net sales	40,069		117,045
Balances without adoption of ASC 606 | Goods Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Net sales	$ 111,786		$ 322,964

Summary of Contract Balances (D

Summary of Contract Balances (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Contract With Customer Asset And Liability [Abstract]
Total receivables, net	$ 137,328	$ 109,605
Contract assets	3,000
Deferred revenue	$ 609	$ 14,574

Summary of Effect of Adoption o

Summary of Effect of Adoption of ASC 606 on Condensed Consolidated Balance Sheet (unaudited) (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets	$ 589,911	$ 535,592
Deferred income tax liabilities, net	17,216	16,284
Retained earnings	256,005	238,953
Adjustment Due to Adoption of ASC 606 | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		3,000
Deferred income tax liabilities, net		786
Retained earnings	2,214	2,214
As adjusted | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		538,592
Deferred income tax liabilities, net		17,070
Retained earnings	$ 253,791	$ 241,167

Summary of Impact of Adoption o

Summary of Impact of Adoption of ASC 606 to Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets:
Contract assets	$ 3,000
Current liabilities:
Deferred revenue	609	$ 14,574
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	256,005	238,953
Accounting Standards Update 2014-09 | Balances without adoption of ASC 606
Current liabilities:
Deferred revenue	550
Stockholders' equity:
Retained earnings	253,791	241,167
Accounting Standards Update 2014-09 | Impact of Adoption of ASC 606
Assets:
Contract assets	3,000
Current liabilities:
Deferred revenue	59
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	$ 2,214	$ 2,214

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total gross value	$ 135,999	$ 134,435
Less accumulated depreciation	(87,684)	(85,114)
Total net value	48,315	49,321
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,548	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	16,832	16,678
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	108,033	107,722
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	5,001	4,925
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	1,102	735
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 2,483	$ 1,917

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 2,020	$ 2,033	$ 6,166	$ 6,112
Elimination of Assets and Accumulated depreciation	$ 249	$ 1,126	$ 3,596	$ 5,884

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 144,963	$ 107,595
Raw materials	17,797	15,529
Total Inventories	$ 162,760	$ 123,124

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory reserve	$ 1,673	$ 1,673	$ 3,137
Amount released to income as a result of adjusted expected future cost	$ 696	$ 696

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net sales
Net sales	$ 111,780	$ 89,975	$ 322,934	$ 238,553
Insecticides
Net sales
Net sales	25,475	24,866	99,433	102,249
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	34,577	32,717	98,163	68,783
Other, Including Plant Growth Regulators
Net sales
Net sales	35,302	17,191	83,519	30,680
Crop
Net sales
Net sales	95,354	74,774	281,115	201,712
Non-Crop
Net sales
Net sales	16,426	15,201	41,819	36,841
US
Net sales
Net sales	71,711	65,842	205,889	173,877
International
Net sales
Net sales	$ 40,069	$ 24,133	$ 117,045	$ 64,676

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Sep. 18, 2018	Jun. 11, 2018	Mar. 8, 2018	Dec. 12, 2017
Cash dividend record date	Oct. 3, 2018	Jun. 28, 2018	Mar. 30, 2018	Dec. 27, 2017
Cash dividend distributed date	Oct. 17, 2018	Jul. 12, 2018	Apr. 13, 2018	Jan. 10, 2018
Cash dividend per share	$ 0.020	$ 0.020	$ 0.020	$ 0.015
Cash dividend paid	$ 588	$ 587	$ 586	$ 438

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator:
Net income attributable to AVD	$ 6,525	$ 4,089	$ 16,779	$ 11,845
Denominator:
Weighted average shares outstanding-basic	29,399	29,193	29,340	29,064
Dilutive effect of stock options and grants	810	590	806	584
Weighted average shares outstanding-assuming dilution	30,209	29,783	30,146	29,648

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Debt Instrument [Line Items]
Short term debt		$ 0	$ 0
Senior secured credit facility, maturity date	Jun. 30, 2022
Revolving Credit Facility
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement				$ 124,724,000
Maximum
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 250,000,000
Consolidated funded debt ratio	325.00%
Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement		$ 105,111,000
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Minimum
Debt Instrument [Line Items]
Consolidated fixed charge covenant ratio	125.00%

Summary of Revolving Line of Cr

Summary of Revolving Line of Credit (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Revolving line of credit	$ 98,100	$ 78,425
Deferred loan fees	(787)	(939)
Net long-term debt	$ 97,313	$ 77,486

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,457	$ 1,263	$ 4,235	$ 3,585
Unamortized Stock-Based Compensation	9,020	6,539	$ 9,020	6,539
Remaining Weighted Average Period (years)			2 years
Unamortized Stock-Based Compensation	6,206		$ 6,206
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 966	$ 635	$ 2,716	$ 2,068
Remaining Weighted Average Period (years)	2 years	1 year 2 months 12 days	2 years	1 year 2 months 12 days
Unamortized Stock-Based Compensation	$ 6,206	$ 4,475	$ 6,206	$ 4,475
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 491	$ 299	$ 1,519	$ 920
Remaining Weighted Average Period (years)	2 years	2 years	2 years	2 years
Unamortized Stock-Based Compensation	$ 2,814	$ 1,901	$ 2,814	$ 1,901
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 80		$ 250
Remaining Weighted Average Period (years)		3 months 18 days		3 months 18 days
Unamortized Stock-Based Compensation		$ 94		$ 94
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 249		$ 347
Remaining Weighted Average Period (years)		3 months 18 days		3 months 18 days
Unamortized Stock-Based Compensation		$ 69		$ 69

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted	0						0
Number of shares vested							19,313
Number of Shares, Expected to Vest	19,760						19,760
Stock-based compensation	$ 1,457			$ 1,263			$ 4,235	$ 3,585
Unamortized Stock-Based Compensation	$ 6,206						$ 6,206
Remaining Weighted Average Period (years)							2 years
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest		77,598
Number of Shares, Granted							0	0
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested	17,591	20,313	8,800	1,065	188,400	10,100		24,312
Number of Shares, Expected to Vest				2,500				2,500
Weighted Average Grant-Date Fair Value, Granted	$ 0	$ 23.66	$ 19.97	$ 19.90	$ 17.08	$ 16.10
Stock-based compensation	$ 966			$ 635			$ 2,716	$ 2,068
Unamortized Stock-Based Compensation	$ 6,206			$ 4,475			$ 6,206	$ 4,475
Remaining Weighted Average Period (years)	2 years			1 year 2 months 12 days			2 years	1 year 2 months 12 days
Number of Shares, Granted	0	22,308	254,972	1,000	38,502	251,475
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested	8,232		14,625		48,046
Weighted Average Grant-Date Fair Value, Granted		$ 22.69	$ 18.79		$ 15.88	$ 15.40	$ 18.74
Stock-based compensation	$ 491			$ 299			$ 1,519	$ 920
Unamortized Stock-Based Compensation	$ 2,814			$ 1,901			$ 2,814	$ 1,901
Remaining Weighted Average Period (years)	2 years			2 years			2 years	2 years
Number of Shares, Granted		3,850	122,446		7,400	121,194	130,332	128,594
Targeted performance percentage	200.00%			200.00%			200.00%	200.00%
Unvested Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation	$ 2,814						$ 2,814
Remaining Weighted Average Period (years)							2 years
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued by equity investee							277,280
Weighted Average Grant-Date Fair Value, Granted							$ 20.27
Common Stock | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued by equity investee								290,977
Weighted Average Grant-Date Fair Value, Granted								$ 16.24
After One Year | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest				1,000				1,000
Number of days of service before cliff vesting								1 year
After One Year | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting							178 days
After One Year | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting							1060 days
After Two Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting							3 years
After Two Year | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting								3 years
Share-based Compensation Award, Tranche Two | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest				2,500				2,500
Number of days of service before cliff vesting								2 years
Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2017 through December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance							80.00%
Earnings before income taxes goal weight, percentage							50.00%
Net sales goal weight, percentage							30.00%
Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2017 through December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage							20.00%
Vested on January 6, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date							Mar. 9, 2021	Feb. 8, 2020
Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2018 and ending December 31, 2020 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance								80.00%
Earnings before income taxes goal weight, percentage								50.00%
Net sales goal weight, percentage								30.00%
Performance based stock options based upon AVD stock price appreciation over the course of the period commencing January 1, 2016 and ending December 31, 2018 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage								20.00%
Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2017 and Ending December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted							$ 18.27
Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2017 and Ending December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted							$ 15.43

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options - $ / shares	3 Months Ended			6 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	394,358	432,718	473,641	473,641
Incentive Stock Option Plans, Option exercised	(9,568)	(38,360)	(40,923)
Incentive Stock Option Plans, Ending balance	384,790	394,358	432,718	394,358
Weighted Average Price Per Share, Beginning balance	$ 9.12	$ 9.19	$ 9.38	$ 9.38
Weighted Average Price Per Share, Option exercised	9.82	10.02	11.49
Weighted Average Price Per Share, Ending balance	9.11	9.12	9.19	9.12
Exercisable Weighted Average Price Per Share, Beginning balance	9.12	9.19	9.38	9.38
Exercisable Weighted Average Price Per Share, Ending balance	$ 9.11	$ 9.12	$ 9.19	$ 9.12

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	384,790
Outstanding Weighted Average, Exercise Price	$ 9.11	$ 9.12	$ 9.19	$ 9.38
Exercisable Weighted Average, Shares	384,790
Exercisable Weighted Average, Exercise Price	$ 9.11	$ 9.12	$ 9.19	$ 9.38
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	229,545
Outstanding Weighted Average, Remaining Life (Months)	26 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Exercisable Weighted Average, Shares	229,545
Exercisable Weighted Average, Exercise Price	$ 7.50
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.75
Outstanding Weighted Average, Shares	155,245
Outstanding Weighted Average, Remaining Life (Months)	73 months
Outstanding Weighted Average, Exercise Price	$ 11.48
Exercisable Weighted Average, Shares	155,245
Exercisable Weighted Average, Exercise Price	$ 11.48

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	19,760
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	384,790
Number of Shares, Expected to Vest	384,790
Number of Shares, Exercisable	384,790
Weighted Average Exercise Price, Outstanding | $ / shares	$ 9.11
Weighted Average Exercise Price, Expected to Vest | $ / shares	9.11
Weighted Average Exercisable, Exercise Price | $ / shares	$ 9.11
Weighted Average Remaining Life, Outstanding	45 months
Weighted Average Remaining Contractual Life, Expected to Vest	45 months
Weighted Average Remaining Contractual Life, Exercisable	45 months
Intrinsic Value, Outstanding | $	$ 3,422
Intrinsic Value, Expected to Vest | $	3,422
Intrinsic Value, Exercisable | $	$ 3,422

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested							(19,313)
Common Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	628,231	632,660	391,753	403,096	559,587	324,756	391,753	324,756
Number of Shares, Granted	0	22,308	254,972	1,000	38,502	251,475
Number of Shares, Vested	(17,591)	(20,313)	(8,800)	(1,065)	(188,400)	(10,100)		(24,312)
Number of Shares, Forfeited	(13,659)	(6,424)	(5,265)	(5,209)	(6,593)	(6,544)
Number of Shares, Ending Balance	596,981	628,231	632,660	397,822	403,096	559,587	596,981	397,822
Weighted Average Grant-Date Fair Value, Beginning balance	$ 17.40	$ 17.41	$ 15.61	$ 15.61	$ 15.38	$ 14.75	$ 15.61	$ 14.75
Weighted Average Grant-Date Fair Value, Granted	0	23.66	19.97	19.90	17.08	16.10
Weighted Average Grant-Date Fair Value, Vested	13.51	22.82	12.07	12.88	15.22	12.95
Weighted Average Grant-Date Fair Value, Forfeited	17.35	17.25	16.51	15.80	15.55	15.26
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.51	$ 17.40	$ 17.41	$ 15.63	$ 15.61	$ 15.38	$ 17.51	$ 15.63

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested							(19,313)
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	293,784	292,113	186,057	187,010	240,216	119,022	186,057	119,022
Number of Shares, Granted		3,850	122,446		7,400	121,194	130,332	128,594
Number of Share, Additional vesting based on performance	4,036
Number of Shares, Vested	(8,232)		(14,625)		(48,046)
Number of Shares, Forfeited	(1,870)	(2,179)	(1,765)	(953)	(12,560)
Number of Shares, Ending Balance	287,718	293,784	292,113	186,057	187,010	240,216	287,718	186,057
Weighted Average Grant-Date Fair Value, Beginning balance	$ 16.81	$ 16.74	$ 14.93	$ 14.93	$ 14.80	$ 14.18	$ 14.93	$ 14.18
Weighted Average Grant-Date Fair Value, Granted		22.69	18.79		15.88	15.40	18.74
Weighted Average Grant-Date Fair Value, Additional vesting based on performance	13.53
Weighted Average Grant-Date Fair Value, Vested	13.47		11.01		14.92
Weighted Average Grant-Date Fair Value, Forfeited	15.67	17.67	15	15.21	12.92
Weighted Average Grant-Date Fair Value, Ending balance	$ 16.87	$ 16.81	$ 16.74	$ 14.93	$ 14.93	$ 14.80	$ 16.87	$ 14.93

Summary of Performance option a

Summary of Performance option activity (Detail)	3 Months Ended	6 Months Ended
	Sep. 30, 2018$ / sharesshares	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Additional vesting based on performance | shares	19,760
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	141,425	81,666
Incentive Stock Option Plans, Additional vesting based on performance | shares		77,598
Incentive Stock Option Plans, Options exercised | shares		(11,839)
Incentive Stock Option Plans, Option forfeited | shares	(1,014)
Incentive Stock Option Plans, Ending balance | shares	140,411	141,425
Weighted Average Price Per Share, Beginning balance	$ 11.49	$ 11.49
Weighted Average Price Per Share, Additional vesting based on performance		11.49
Weighted Average Price Per Share, Options exercised		11.49
Weighted Average Price Per Share, Option forfeited	11.49
Weighted Average Price Per Share, Ending balance	11.49	11.49
Exercisable Weighted Average Price Per Share, Beginning balance	11.49	11.49
Exercisable Weighted Average Price Per Share, Ending balance	$ 11.49	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan - $ / shares	9 Months Ended
	Sep. 30, 2018	Aug. 21, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares		140,411
Outstanding Weighted Average, Remaining Life (Months)	75 months
Outstanding Weighted Average, Exercise Price	$ 11.49
Exercisable Weighted Average, Shares	140,411
Exercisable Weighted Average, Exercise Price	$ 11.49

Performance Option Weighted Ave

Performance Option Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	19,760
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	140,411
Number of Shares, Expected to Vest	140,411
Number of Shares, Exercisable	140,411
Weighted Average Exercise Price, Outstanding | $ / shares	$ 11.49
Weighted Average Exercise Price, Expected to Vest | $ / shares	11.49
Weighted Average Exercisable, Exercise Price | $ / shares	$ 11.49
Weighted Average Remaining Life, Outstanding	75 months
Weighted Average Remaining Contractual Life, Expected to Vest	75 months
Weighted Average Remaining Contractual Life, Exercisable	75 months
Intrinsic Value, Outstanding | $	$ 914
Intrinsic Value, Expected to Vest | $	914
Intrinsic Value, Exercisable | $	$ 914

Recently Issued Accounting Gu_2

Recently Issued Accounting Guidance - Additional Information (Detail) $ in Thousands	Jan. 01, 2018USD ($)
Adopted ASU 2016-16
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reduction to retained earnings	$ (180)

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
AgriCenter
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deferred consideration adjustment	$ 0	$ 1,146
AgriCenter and OHP | General and Administrative Expenses
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deferred consideration adjustment	$ 3,969	$ 5,437

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 320,231	$ 314,158	$ 305,314		$ 305,314
Foreign currency translation adjustment	638	(898)	672	$ (67)	412	$ 970
Balance	328,624	320,231	314,158		328,624
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(4,733)	(3,835)	(4,507)		(4,507)
Foreign currency translation adjustment	638	(898)	672
Balance	$ (4,095)	$ (4,733)	$ (3,835)		$ (4,095)

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 07, 2017	Jun. 27, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 31, 2018	Dec. 31, 2017
Equity Method Investments [Line Items]
Gain (loss) from equity method investment					$ (1,051)	$ (226)
Investment		$ 950				950
Bi-PA
Equity Method Investments [Line Items]
Equity investment ownership position			15.00%		15.00%
Impairment on the investment					$ 0
Profeng Australia, Pty Ltd
Equity Method Investments [Line Items]
Joint venture, consideration	$ 1,900
TyraTech Inc.
Equity Method Investments [Line Items]
Equity investment ownership position							34.38%	15.11%
Gain (loss) from equity method investment			$ (352)	$ (29)	$ (795)	(140)
Hong Kong JV
Equity Method Investments [Line Items]
Equity investment ownership position			50.00%		50.00%
Gain (loss) from equity method investment			$ (182)	$ (86)	$ (256)	$ (86)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Taxes [Line Items]
Increase in income tax expense	$ 1,572
Income tax expense	3,526	$ 1,954	$ 6,966	$ 5,015
One time income tax adjustment related tax cuts and jobs act	$ 1,089
Federal income tax rate			21.00%		35.00%
Effective tax rate without adjustments	23.10%		23.80%
Scenario, Plan
Income Taxes [Line Items]
Federal income tax rate	33.40%	32.10%	28.20%	29.20%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event - USD ($) $ in Thousands	Oct. 31, 2018	Nov. 02, 2018
Subsequent Event [Line Items]
Stock Repurchase Program, Authorized Amount		$ 20,000
TyraTech Inc.
Subsequent Event [Line Items]
Percentage of issued and outstanding shares acquired	65.62%
Business acquisition of cash consideration	$ 4,340
Transaction expected closing date	Nov. 8, 2018